Metamark

The proteomic test identifies prostate cancer patients with likely non-aggressive forms of the disease that can be treated without surgery or radiation therapy.

The insurer will cover Metamark's urology specialized diagnostics throughout the state.

The deal is the latest coverage and reimbursement success for the Cambridge, Massachusetts-based urology diagnostics firm.

Medicare contractors Palmetto GBA, Noridian Healthcare Solutions, and CGS Administrators have all proposed reimbursement coverage for the ProMark test.

The companies have also agreed to co-develop a second-generation version of the assay, which will run on Hologic's Panther instrument system.

The study, by Fred Hutchinson researchers consulting with Metamark, found the test offers increased quality-adjusted life-years and a decrease in costs.

The funding will be used to further expand the company's clinical testing products and services in the US and abroad.

The deal provides access to Metamark's diagnostic and prognostic tests for urology to 5.2 million Highmark Blue Shield members in Delaware, Pennsylvania, and West Virginia.

Since launching it in June, the firm has sold roughly 1,000 tests. It measures eight proteins to determine the likelihood that a patient's cancer is aggressive.

The laboratory will serve as the primary processor for the company's protein-based prostate cancer test called ProMark.

Pages

A new analysis examines the gender gap among paper authors in the sciences and says it may take decades or more to close.

Researchers have uncovered signals of selection that may enable the Bajau people to free five hundreds of feet deep, Reuters reports.

In Science this week: paternally inherited cis-regulatory structural variants in autism, and more.

A new report outlines issues facing the implementation of personalized medicine in the UK, the Independent reports.